Initial Performance of NI-RADS to Predict Residual or Recurrent Head and Neck Squamous Cell Carcinoma

被引:49
|
作者
Krieger, D. A. [1 ]
Hudgins, P. A. [2 ]
Nayak, G. K. [7 ]
Baugnon, K. L. [2 ]
Corey, A. S. [2 ]
Patel, M. R. [3 ]
Beitler, J. J. [3 ,4 ,5 ]
Saba, N. F. [5 ]
Liu, Y. [6 ]
Aiken, A. H. [2 ]
机构
[1] Hackensack Univ Med Ctr, Dept Radiol, Hackensack, NJ USA
[2] Emory Univ, Sch Med, Dept Radiol & Imaging Sci, Atlanta, GA USA
[3] Emory Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Atlanta, GA USA
[4] Emory Univ, Sch Med, Winship Canc Inst, Dept Radiat Oncol, Atlanta, GA USA
[5] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA
[6] Emory Univ, Sch Med, Dept Biostat, Winship Canc Inst, Atlanta, GA USA
[7] NYU, Dept Radiol, Sch Med, 560 1st Ave, New York, NY 10016 USA
关键词
SURVEILLANCE PET/CT; CANCER; UTILITY;
D O I
10.3174/ajnr.A5157
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BACKGROUND AND PURPOSE: The Head and Neck Imaging Reporting and Data System (NI-RADS) surveillance template for head and neck cancer includes a numeric assessment of suspicion for recurrence (1-4) for the primary site and neck. Category 1 indicates no evidence of recurrence; category 2, low suspicion of recurrence; category 3, high suspicion of recurrence; and category 4, known recurrence. Our purpose was to evaluate the performance of the NI-RADS scoring system to predict local and regional disease recurrence or persistence. MATERIALS AND METHODS: This study was classified as a quality-improvement project by the institutional review board. A retrospective database search yielded 500 consecutive cases interpreted using the NI-RADS template. Cases without a numeric score, non-squamous cell carcinoma primary tumors, and primary squamous cell carcinoma outside the head and neck were excluded. The electronic medical record was reviewed to determine the subsequent management, pathology results, and outcome of clinical and radiologic follow-up. RESULTS: A total of 318 scans and 618 targets (314 primary targets and 304 nodal targets) met the inclusion criteria. Among the 618 targets, 85.4% were scored NI-RADS 1; 9.4% were scored NI-RADS 2; and 5.2% were scored NI-RADS 3. The rates of positive disease were 3.79%, 17.2%, and 59.4% for each NI-RADS category, respectively. Univariate association analysis demonstrated a strong association between the NI-RADS score and ultimate disease recurrence, with P < .001 for primary and regional sites. CONCLUSIONS: The baseline performance of NI-RADS was good, demonstrating significant discrimination among the categories 1-3 for predicting disease.
引用
收藏
页码:1193 / 1199
页数:7
相关论文
共 50 条
  • [21] Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)-a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma
    Flach, Susanne
    Howarth, Karen
    Hackinger, Sophie
    Pipinikas, Christodoulos
    Ellis, Pete
    McLay, Kirsten
    Marsico, Giovanni
    Forshew, Tim
    Walz, Christoph
    Reichel, Christoph A.
    Gires, Olivier
    Canis, Martin
    Baumeister, Philipp
    BRITISH JOURNAL OF CANCER, 2022, 126 (08) : 1186 - 1195
  • [22] Evaluation of Proton Therapy Reirradiation for Patients With Recurrent Head and Neck Squamous Cell Carcinoma
    Lee, Anna
    Woods, Robbie
    Mahfouz, Amgad
    Kitpanit, Sarin
    Cartano, Olivia
    Mohamed, Nader
    Youssef, Irini
    Marqueen, Kathryn
    Sine, Kevin
    Mah, Dennis
    Neal, Brian
    Zakeri, Kaveh
    Kang, Jung J.
    Riaz, Nadeem
    Yu, Yao
    McBride, Sean M.
    Chen, Linda D.
    Tsai, C. Jillian
    Gelblum, Daphna Y.
    Press, Robert H.
    Michel, Loren S.
    Sherman, Eric J.
    Pfister, David
    Dunn, Lara A.
    Ho, Alan L.
    Fetten, James
    Wong, Richard J.
    Boyle, Jay O.
    Singh, Bhuvanesh
    Cracchiolo, Jennifer R.
    Ganly, Ian
    Cohen, Marc A.
    Lee, Nancy Y.
    JAMA NETWORK OPEN, 2023, 6 (01) : e2250607
  • [23] Interstitial photodynamic therapy in combination with Cetuximab for recurrent head and neck squamous cell carcinoma
    Rigual, Nestor
    Dildeep, Ambujakshan
    Shafirstein, Gal
    PHOTONIC THERAPEUTICS AND DIAGNOSTICS IX, 2013, 8565
  • [24] Review of Outcomes after Salvage Surgery for Recurrent Squamous Cell Carcinoma of the Head and Neck
    Hartl, Dana M.
    Guerlain, Joanne
    Gorphe, Philippe
    Kapre, Madan
    Kapre Gupta, Neeti
    Saba, Nabil F.
    Robbins, K. Thomas
    Ronen, Ohad
    Rodrigo, Juan P.
    Strojan, Primoz
    Maekitie, Antti A.
    Kowalski, Luiz P.
    Shah, Jatin P.
    Ferlito, Alfio
    CANCERS, 2023, 15 (19)
  • [25] A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
    de Souza, Jonas A.
    Davis, Darren W.
    Zhang, Yujian
    Khattri, Arun
    Seiwert, Tanguy Y.
    Aktolga, Serdal
    Wong, Stuart J.
    Kozloff, Mark F.
    Nattam, Sreenivasa
    Lingen, Mark W.
    Kunnavakkam, Rangesh
    Stenson, Kerstin M.
    Blair, Elizabeth A.
    Bozeman, Jeffrey
    Dancey, Janet E.
    Vokes, Everett E.
    Cohen, Ezra E. W.
    CLINICAL CANCER RESEARCH, 2012, 18 (08) : 2336 - 2343
  • [26] Opportunities and Limits in Salvage Surgery in Persistent or Recurrent Head and Neck Squamous Cell Carcinoma
    Huber, Gerhard Frank
    CANCERS, 2021, 13 (10)
  • [27] Combined Cetuximab and Reirradiation for Locoregional Recurrent and Inoperable Squamous Cell Carcinoma of the Head and Neck
    Balermpas, Panagiotis
    Hambek, Markus
    Seitz, Oliver
    Roedel, Claus
    Weiss, Christian
    STRAHLENTHERAPIE UND ONKOLOGIE, 2009, 185 (12) : 775 - 781
  • [28] PD-L1 expression in recurrent head and neck squamous cell carcinoma
    Delafoy, Alice
    Uguen, Arnaud
    Lemasson, Gilles
    Conan-Charlet, Virginie
    Pradier, Olivier
    Lucia, Francois
    Schick, Ulrike
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2022, 279 (01) : 343 - 351
  • [29] A Metabolic Gene Signature to Predict Overall Survival in Head and Neck Squamous Cell Carcinoma
    Wu, Zeng-Hong
    Tang, Yun
    Zhou, Yue
    MEDIATORS OF INFLAMMATION, 2020, 2020
  • [30] Current status of systemic therapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Jacob, L. A.
    Chaudhuri, T.
    Lakshmaiah, K. C.
    Babu, K. G.
    Dasappa, L.
    Babu, M. C. S.
    Rudresha, A. H.
    Lokesh, K. N.
    Rajeev, L. K.
    INDIAN JOURNAL OF CANCER, 2016, 53 (04) : 1 - 7